Cardiff Oncology posts new data for lead program in colorectal cancer

Jan. 19, 2022 7:12 AM ETCardiff Oncology, Inc. (CRDF)By: Dulan Lokuwithana, SA News Editor9 Comments

Cancer cells vis

koto_feja/E+ via Getty Images

  • Cardiff Oncology (NASDAQ:CRDF) is trading ~16.3% lower in the pre-market after updating data from its lead clinical program for onvansertib/ standard-of-care (SOC) FOLFIRI/bevacizumab.
  • The Phase 1b/2 trial is designed to assess the therapeutic combination as a second-line option for patients with KRAS-mutated metastatic colorectal cancer (mCRC).
  • A section of the data will be part of a presentation scheduled for Saturday at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCOGI).
  • The results that included patient follow-up data collected after the cutoff dates for ASCO-GI abstract and poster indicate that 17 of 48 (35%) patients across all dose levels achieved a complete response (CR) or partial response (PR).
  • Median progression-free survival (mPFS) across response-evaluable patients (n=48) stood at 9.4 months, and mPFS did not reach in those treated per protocol at the RP2D.
  • However, 5 of 48 (10%) patients had discontinued the trial to seek metastasis-directed treatments such as surgical resection or microwave ablation. 11% (84/788) of all patients reported treatment-emergent adverse events (TEAEs) at Grade 3 or Grade 4.
  • Ratings: Cardiff Oncology (CRDF) has attracted overwhelmingly Bullish ratings on Wall Street.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.